| Regulatory status | PHASE 3 |
|---|---|
| Mechanism | Triple GIP / GLP-1 / glucagon receptor agonist |
| Developer | Eli Lilly |
| Form | Lyophilized powder · 10mg, 30mg, 60mg, 100mg |
| CAS | 2381089-83-2 |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Retatrutide adds glucagon receptor agonism to the dual incretin backbone — recruiting energy expenditure alongside appetite regulation. Its phase 2 readout in the New England Journal of Medicine posted the largest mean weight reduction ever reported in an obesity trial at the time. Phase 3 (TRIUMPH) is underway.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
Three receptors, one molecule. The most ambitious incretin in development.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
